Page last updated: 2024-12-10
normacromerine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
normacromerine: RN given refers to cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 3084840 |
SCHEMBL ID | 3652526 |
MeSH ID | M0043474 |
Synonyms (20)
Synonym |
---|
1-(3,4-dimethoxyphenyl)-2-(methylamino)ethan-1-ol |
normacromerine |
1-(3,4-dimethoxyphenyl)-2-(methylamino)ethanol |
AKOS009461884 |
FT-0673104 |
5653-66-7 |
n-methyl-3,4-dimethoxy-beta-hydroxy-beta-phenethylamine |
benzenemethanol, 3,4-dimethoxy-alpha-((methylamino)methyl)- |
2-(3,4-dimethoxyphenyl)-2-hydroxy-n-methylethylamine |
AS-871/43475618 |
SCHEMBL3652526 |
1-(3,4-dimethoxyphenyl)-2-methylamino-ethanol |
mfcd08060992 |
n-methyl-3,4-dimethoxyphenylethanolamine |
NS-02372 |
1-(3,4-dimethoxyphenyl)-2-methylaminoethanol |
FT-0738202 |
DTXSID80961983 |
benzenemethanol, 3,4-dimethoxy-?-[(methylamino)methyl]- |
EN300-1828208 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 5 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.66
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |